2023.01.15Vol.5 No.1 NEWS We have recently uploaded the Partial Amendments to Postmarketing Adverse Reaction Reporting and Study Adverse Reaction Reporting in Response to E2B (R3) Implementation Guide (2022/2/7 and 2022/6/24) to the Reference Page.
2022.12.20Vol.4 No.10 NEWS We have recently uploaded the May 31, 2022 (English translation) Q&A on Early post-marketing phase vigilance (EPPV) of Medicinal Products to the Reference Page.
2022.12.15Vol.4 No.9 NEWS 1)Pharmaron Clinical Provides comprehensive service support for drug clinical development, clinical trials, safety management, regulatory compliance and post-marketing management in China.
2022.12.07Vol.4 No.7 NEWS [MHRA_Guidance on pharmacovigilance procedures - GOV_Japanese.pdf] Webpage Reference Uploaded.
2022.05.11Vol.3 No.11 NEWS Updates for Electronic Submission of Individual Case Safety Reports (ICSRs) to FAERS: on 29-Apr-2022
2022.03.08Vol.3 No.10 NEWS Procedures for obtaining an Electronic Digital Certificates for ICSR electronic Safety Information Reporting : MEDIS
2021.10.30Vol.3 No.8 NEWS Good Machine Learning Practice (GMLP) for Medical Device Development: Guiding Principles by FDA, Health Canada, and MHRA
2021.09.06Vol.3 No.7 NEWS Two Q&As about a Regulations of AE Reports in China(NMPA) and Source Korea(MFDS)